Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909706 | 0.98 | EPHX1 (0.46) | KMT2AEPHX1HPGDEPHX2MGAM | |
| SCHEMBL28055530 | 0.96 | MGAM (0.39) | KMT2AEPHX1HPGDEPHX2MGAM | |
| SCHEMBL3956402 | 0.91 | MGAM (0.42) | KMT2AEPHX1HPGDEPHX2MGAM | |
| SCHEMBL868953 | 0.85 | BRD4 (0.47) | KMT2AEPHX1HPGDEPHX2ALDH1A1 | |
| SCHEMBL10584364 | 0.84 | EPHX1 (0.44) | KMT2AEPHX1HPGDEPHX2L3MBTL1 | |
| SCHEMBL106265 | 0.83 | KMT2A (0.50) | KMT2AEPHX1HPGDEPHX2ALDH1A1 | |
| SCHEMBL8099254 | 0.83 | KMT2A (0.50) | KMT2AEPHX1HPGDEPHX2ALDH1A1 | |
| SCHEMBL14606391 | 0.83 | KMT2A (0.50) | KMT2AEPHX1HPGDEPHX2ALDH1A1 | |
| SCHEMBL28207514 | 0.83 | BRD4 (0.46) | KMT2AEPHX1HPGDEPHX2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27660647 | 0.83 | BRD4 (0.46) | KMT2AEPHX1HPGDEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | KMT2A 1860/4885EPHX1 293/4885HPGD 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.